Emerald Mutual Fund Advisers Trust Sells 5,011 Shares of Insmed, Inc. $INSM

Emerald Mutual Fund Advisers Trust reduced its position in Insmed, Inc. (NASDAQ:INSM) by 37.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,230 shares of the biopharmaceutical company’s stock after selling 5,011 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in Insmed were worth $1,346,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in Insmed by 18.8% in the 1st quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company’s stock worth $149,860,000 after acquiring an additional 145,106 shares during the last quarter. J. Safra Sarasin Holding AG boosted its position in shares of Insmed by 1,342.2% during the 1st quarter. J. Safra Sarasin Holding AG now owns 93,181 shares of the biopharmaceutical company’s stock valued at $15,235,000 after acquiring an additional 86,720 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Insmed by 111.8% during the 1st quarter. International Assets Investment Management LLC now owns 699 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 369 shares during the last quarter. Diversify Wealth Management LLC purchased a new position in shares of Insmed in the first quarter valued at $279,000. Finally, Fifth Third Bancorp grew its holdings in shares of Insmed by 4,983.8% in the first quarter. Fifth Third Bancorp now owns 18,200 shares of the biopharmaceutical company’s stock valued at $2,976,000 after purchasing an additional 17,842 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. Royal Bank Of Canada lowered their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $166.00 to $212.00 in a report on Monday, March 30th. Finally, Wells Fargo & Company decreased their target price on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Insmed currently has a consensus rating of “Moderate Buy” and an average price target of $211.00.

Insider Activity

In related news, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the transaction, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. The trade was a 3.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Michael Alexander Smith sold 1,806 shares of Insmed stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the transaction, the insider directly owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 65,289 shares of company stock worth $7,334,073 over the last 90 days. Insiders own 2.10% of the company’s stock.

Insmed Stock Performance

NASDAQ:INSM opened at $109.14 on Tuesday. The firm has a market capitalization of $23.66 billion, a PE ratio of -18.98 and a beta of 0.78. The stock’s fifty day moving average is $106.67 and its 200 day moving average is $137.53. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. During the same period in the previous year, the firm earned ($1.42) earnings per share. Insmed’s quarterly revenue was up 229.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Insmed, Inc. will post -2.55 earnings per share for the current year.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.